Mounjaro® / Zepbound®
Tirzepatide Injection
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$1,069
With Insurance
$25–200
FDA Black Box Warning
THYROID C-CELL TUMORS
Tirzepatide causes dose-dependent thyroid C-cell tumors in rodents. Human relevance is unknown. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
Strict Contraindications
How It Works
Tirzepatide is unique: it activates both the GLP-1 receptor (like Ozempic) and the GIP receptor simultaneously. GIP is the "incretin" released when you eat fat and protein. At pharmacological doses, this dual activation produces appetite suppression and weight loss that exceeds any single-receptor agonist — but it is essentially forcing your body to feel full at a level no natural meal achieves.
Why the side effects happen
Nausea and vomiting are more intense with tirzepatide than semaglutide, particularly at higher doses (10mg–15mg), because both GIP and GLP-1 receptors slow gastric emptying simultaneously. The dose-escalation schedule (2.5mg every 4 weeks) exists specifically to let the gut adapt. Hair thinning (telogen effluvium) is not a drug side effect — it is a response to rapid weight loss and caloric restriction; adequate protein (1g/lb lean mass) dramatically reduces it.
When Will I Feel It?
Appetite suppression begins in week 1. Meaningful weight loss builds over months. Maximum effect at the highest tolerated dose typically reached by month 5–9 due to the escalation schedule.
Subtle appetite reduction begins. Nausea is common but usually mild at the starting dose. Most people lose 1–3 lbs in this phase.
Dose escalation phase. Nausea peaks during transitions between doses. Average weight loss: 4–7% of body weight.
Accelerated weight loss. SURMOUNT-1 showed most of the weight-loss trajectory is established by month 6.
Plateau at maximum dose. SURMOUNT-1 showed 22.5% average weight loss at 72 weeks on 15mg. Individual results vary widely.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Nausea
31–36%Worst during dose escalation; eat smaller meals; avoid greasy and high-volume foods
Diarrhea
20–23%Usually self-limiting; stay hydrated with electrolytes; usually improves after 4–8 weeks
Vomiting
13–16%Most common at dose escalation; avoid large meals; take with a small snack if needed
Constipation
17–19%Increase fiber and water; magnesium glycinate 200–400mg nightly can help
Decreased appetite
40%+Expected and intentional; ensure adequate protein (1g/lb lean mass) to protect muscle mass
Abdominal pain / cramping
10–12%Eat slowly; avoid carbonated drinks; smaller, more frequent meals
Injection site reaction
6–7%Rotate injection sites each week; inject into abdomen, thigh, or upper arm
Fatigue
6%Often related to caloric restriction; ensure adequate calories and protein; monitor for anemia
Belching / indigestion (GERD)
8%Avoid eating within 2–3 hours of lying down; smaller meals; elevate head of bed
Hair thinning (telogen effluvium)
5%Caused by rapid weight loss, not the drug itself; ensure adequate protein and micronutrients (zinc, biotin)
Serious Adverse Effects
- • Pancreatitis (<1%) — discontinue and do not restart if confirmed
- • Gallbladder disease / gallstones (rapid weight loss increases risk)
- • Kidney injury (from dehydration, not direct nephrotoxicity)
- • Thyroid tumors (see Black Box)
- • Diabetic retinopathy worsening (rapid glucose reduction)
- • Hypoglycemia (especially if on insulin or sulfonylurea)
- • Severe GI events requiring hospitalization
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Pancreatitis — discontinue and do not restart if confirmed
- Gallbladder disease / gallstones (rapid weight loss increases risk)
- Kidney injury (from dehydration, not direct nephrotoxicity)
- Thyroid tumors
- Rapid weight regain (>5 lbs in 2 weeks)
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Animal studies show fetal harm at human-equivalent doses. Stop Mounjaro/Zepbound at least 1 month before planned pregnancy. No adequate human data exists.
Unknown whether tirzepatide is present in human milk. Given its molecular weight and mechanism, avoidance during breastfeeding is recommended.
Estrogen decline at menopause drives visceral fat redistribution, insulin resistance, and the same cardiometabolic risk profile that tirzepatide targets. This means some of the "weight gain at menopause" is hormonally driven — not purely behavioral. Tirzepatide may be especially effective in this population, but ask your doctor whether estrogen replacement should be considered first, particularly if menopause symptoms are present.
Mounjaro approved for T2D in adolescents ≥10 years (2024). Zepbound not approved under 18. Long-term growth and developmental effects in pediatric use are unknown.
No pharmacokinetic difference. Watch closely for dehydration, falls, and muscle loss (sarcopenia) — older adults losing weight on tirzepatide may lose disproportionate muscle without adequate protein and resistance training.
No dose adjustment needed in renal impairment. However, GI side effects causing dehydration can worsen existing kidney disease — monitor hydration and eGFR.
No dose adjustment required in hepatic impairment. Fatty liver often improves substantially with weight loss on tirzepatide — one of the unintended benefits.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Metabolic Root-Cause Alternatives
Tirzepatide's dual GIP/GLP-1 action achieves 20–22% weight loss partly by mimicking the satiety signals your body already produces from protein and fat — signals that are blunted when a diet is dominated by refined carbohydrates. A very-low-carbohydrate diet removes the hyperinsulinemia that drives fat storage and can restore these natural signaling pathways without a $1,000/month drug. Virta Health's 2-year RCT achieved 53% T2D remission with dietary change alone. The driver of obesity and T2D is not dietary fat — it is chronic carbohydrate overload triggering hyperinsulinemia and de novo lipogenesis.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Ketogenic / Very Low-Carbohydrate Diet (<20–30g net carbs/day)
Eliminates the glucose spikes driving beta-cell exhaustion and fat storage; protein and dietary fat naturally stimulate GIP and GLP-1 in physiological doses — the same signaling tirzepatide amplifies pharmacologically
HbA1c reduction of 1.0–1.5% sustained at 2 years; 53% T2D remission in Virta 2-year RCT; triglycerides down 40–50%; LDL shifts to large buoyant particles. 94% of Virta participants reduced or eliminated diabetes medications.
Protein-Forward Eating (1.2–1.6g protein per kg body weight)
High protein intake is the most potent natural stimulator of GLP-1 and GIP secretion — satiety hormones that tirzepatide mimics. Protein also preserves lean muscle mass during weight loss.
High-protein diets produce superior satiety, 25% greater fat loss vs. standard-protein during caloric restriction, and better preservation of metabolic rate during weight loss.
Time-Restricted Eating (16:8 or 18:6 window)
Compresses insulin-elevated time, restores insulin sensitivity, and activates autophagy pathways without requiring caloric counting
Improves fasting insulin, HbA1c, and visceral fat independently of caloric restriction. Pairs especially well with low-carb.
Resistance Training (3–4×/week, compound movements)
Critical when using GLP-1/GIP drugs — rapid weight loss includes muscle loss; resistance training is the only proven intervention to offset this
Increases GLUT4 transporter density in muscle; improves glucose disposal by 48%; reduces visceral adipose tissue; helps preserve lean mass during drug-induced weight loss.
Berberine (500mg 3×/day with meals)
AMPK activator — activates the same cellular pathway as metformin; reduces hepatic glucose output and improves insulin sensitivity
Multiple RCTs show HbA1c reduction equivalent to metformin; lowers LDL and triglycerides; available OTC without a prescription.
How It Compares
Tirzepatide (Mounjaro/Zepbound) produces 20–22% average weight loss vs. ~15% for semaglutide (Wegovy). However, both require indefinite use — SURMOUNT-4 and STEP 4 both show full regain within 1 year of stopping. Tirzepatide has a longer dose-escalation schedule and higher early GI side-effect burden.
Strengths
- Greater weight loss than any approved single-agent GLP-1 agonist
- Approved for both diabetes and obesity in one molecule
- Once-weekly pen injection
- Cardiovascular outcomes data (SURPASS-CVOT)
Weaknesses
- More intense GI side effects at higher doses vs. semaglutide
- $1,069/month list price; many insurance plans exclude Zepbound for obesity
- No oral formulation (unlike Rybelsus for semaglutide)
- Full weight regain within 1 year of stopping
- Only 4–6 years of post-market data
Clinically Preferred Alternatives
Global Prescribing & Pricing
US prescribes tirzepatide at 8–10× the rate of Europe; supply shortages persisted through 2024
United States
$1,069 (list)/mo
Fastest-growing drug in US history by revenue; DTC advertising began 2023
Medicare Part D covers Mounjaro for diabetes but excluded Zepbound for obesity under most plans until 2025
Highly variable; prior auth required; many commercial plans exclude Zepbound for obesity
United Kingdom
~$130/mo
NICE approved tirzepatide for T2D in 2023; obesity approval pending NHS rollout timeline
BMI ≥35 plus T2D or established CVD required; 2-year NHS pathway before initiation
Covered by NHS with strict BMI, T2D, and lifestyle criteria; obesity indication under phased rollout
Germany
~$150/mo
Approved for T2D; obesity reimbursement highly restricted
Statutory insurers can reject reimbursement for obesity without T2D comorbidity; lifestyle prerequisite required
T2D covered; obesity often excluded or self-pay
France
~$80/mo
Approved for T2D; obesity indication reimbursement tied to HAS guidelines
6-month structured lifestyle program mandatory before any GLP-1/GIP drug for obesity; sugar beverage tax funds the program
T2D reimbursed fully; obesity indications require documented lifestyle failure
Japan
~$90/mo
Approved for T2D in 2023; obesity not approved
Japan uses tirzepatide only for diabetes; lower obesity rates mean appetite for obesity drugs is limited; maximum doses lower than US
T2D covered under JHIS; obesity not approved
The same Mounjaro pen costs $1,069/month in the US and under $130 in the UK — an 8× price difference for the same molecule made by the same company. The UK requires patients to have failed supervised lifestyle programs. The US requires a prescription and a credit card.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
All SURPASS and SURMOUNT trials were designed, funded, and controlled by Eli Lilly. Lilly reported $5.8B in tirzepatide revenue in 2024 alone — its fastest product ramp in history. Lead investigators across all trials received advisory fees, speaker payments, and research grants from Lilly. The company employs the investigators, owns the patient-level data, and controls publication timing.
Declared Conflicts of Interest
Eli Lilly's DTC marketing budget for tirzepatide exceeds $1B annually. Key obesity researchers who co-authored trial publications receive six-figure consulting fees from Lilly and other GLP-1 manufacturers. The Obesity Society and American Diabetes Association both receive substantial pharmaceutical funding. SURMOUNT-4's withdrawal arm — showing full weight regain within 1 year of stopping — received minimal media attention compared to the initial weight-loss results.
Key Efficacy Results
Expected HbA1c reduction: −1.87% to −2.46% from baseline (SURPASS-1, 5–15mg). SURPASS-2: tirzepatide superior to semaglutide 1mg for HbA1c. SURMOUNT-1: −22.5% body weight at 72 weeks (15mg). SURMOUNT-4: full weight regain within 1 year of stopping — documented in the withdrawal arm.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Tirzepatide Injection. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Tirzepatide Injection in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| SURPASS-1 (Lilly) | NCT03954834 | |
| SURPASS-2 (Lilly) | NCT03987919 | |
| SURPASS-3 (Lilly) | NCT03882970 | |
| SURPASS-5 (Lilly) | NCT04039503 | |
| SURMOUNT-1 (Lilly) | NCT04184622 | |
| SURMOUNT-2 (Lilly) | NCT04657003 | |
| SURMOUNT-4 (Lilly) | NCT04660643 | |
| SURPASS-CVOT (Lilly) | NCT04255433 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
SURMOUNT-4's withdrawal arm is unambiguous: patients who stopped tirzepatide after achieving 20%+ weight loss regained the majority of that weight within 1 year. This is not a willpower problem — it is a hormonal rebound. Baseline hunger hormones (ghrelin) resurge when the drug is discontinued. Stopping without a lifestyle foundation virtually guarantees regain.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Research supports establishing a dietary pattern (low-carb or protein-forward) that can sustain weight independently before reducing dose
- ·Research identifies resistance training (3×/week minimum) as the most important factor for muscle mass preservation and long-term weight maintenance after stopping
- ·Published protocols describe reducing by one dose increment (e.g., 15mg → 12.5mg → 10mg) over 4–6 weeks with weight monitoring at each step
- ·Research suggests pausing dose reduction and stabilizing if weight regain exceeds 5% during the stopping process
- ·Clinical guidelines suggest monitoring HbA1c at 3 months after stopping in patients who were using it for T2D
Warning Symptoms — Contact Your Doctor If You Experience:
- Rapid weight regain (>5 lbs in 2 weeks)
- Rising blood glucose above target if used for T2D
- Return of intense food cravings and hunger within 1–2 weeks of stopping
- Worsening HbA1c at follow-up bloodwork
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Am I on this for diabetes control, weight management, or both — and does that change which brand I use?
- 2.What happens to my weight when I stop — and what is the plan for that?
- 3.Should I start resistance training now to protect my muscle mass while losing weight?
- 4.Have we tried low-carbohydrate dietary changes first, or in combination?
- 5.What is the plan if my insurance stops covering this in the future?
Lab Tests to Request
- HbA1c (baseline and at 3 months)
- Fasting glucose and insulin (to assess insulin resistance)
- Thyroid (TSH + calcitonin if history of thyroid disease)
- Kidney function (eGFR + creatinine)
- Lipid panel
- Liver enzymes (ALT/AST — fatty liver common at baseline)
- Body composition scan (DEXA) if available — to track muscle vs. fat loss
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Mounjaro® / Zepbound®
- What is Mounjaro® / Zepbound® used for?
- Mounjaro® / Zepbound® (Tirzepatide Injection) is a GIP/GLP-1 Dual Receptor Agonist manufactured by Eli Lilly. FDA-approved indications include: Type 2 diabetes (Mounjaro); Chronic weight management — obesity or overweight with comorbidity (Zepbound); Cardiovascular risk reduction (approved Jan 2025 for Zepbound in CVD patients).
- What are the common side effects of Mounjaro® / Zepbound®?
- Common side effects of Mounjaro® / Zepbound® include: Nausea (31–36%); Diarrhea (20–23%); Vomiting (13–16%); Constipation (17–19%); Decreased appetite (40%+).
- How much does Mounjaro® / Zepbound® cost?
- Mounjaro® / Zepbound® list price is approximately $1,069. With insurance it typically costs $25–200; without insurance approximately $600–1,100.
- Who funded the clinical trials for Mounjaro® / Zepbound®?
- All SURPASS and SURMOUNT trials were designed, funded, and controlled by Eli Lilly. Lilly reported $5.8B in tirzepatide revenue in 2024 alone — its fastest product ramp in history. Lead investigators across all trials received advisory fees, speaker payments, and research grants from Lilly. The company employs the investigators, owns the patient-level data, and controls publication timing.
- How strong is the clinical evidence for Mounjaro® / Zepbound®?
- Key studies: SURPASS-1 through SURPASS-5, SURMOUNT-1 through SURMOUNT-4, SURPASS-CVOT. Expected HbA1c reduction: −1.87% to −2.46% from baseline (SURPASS-1, 5–15mg). SURPASS-2: tirzepatide superior to semaglutide 1mg for HbA1c. SURMOUNT-1: −22.5% body weight at 72 weeks (15mg). SURMOUNT-4: full weight regain within 1 year of stopping — documented in the withdrawal arm. Potential conflicts of interest: Eli Lilly's DTC marketing budget for tirzepatide exceeds $1B annually. Key obesity researchers who co-authored trial publications receive six-figure consulting fees from Lilly and other GLP-1 manufact.
- Are there non-drug alternatives to Mounjaro® / Zepbound®?
- Tirzepatide's dual GIP/GLP-1 action achieves 20–22% weight loss partly by mimicking the satiety signals your body already produces from protein and fat — signals that are blunted when a diet is dominated by refined carbohydrates. A very-low-carbohydrate diet removes the hyperinsulinemia that drives See the Alternatives tab for full details.
Get notified when we update Mounjaro® / Zepbound®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.